NCT02936323 - PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

February 25, 2021

Conditions

Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma

Interventions

DRUG

PEN-221

PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.

DRUG

PEN-221

PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.

Trial Locations (13)

10032

Columbia University Medical Center/ NY Presbyterian, Manhattan

33705

Florida Cancer Specialists North, St. Petersburg

33901

Florida Cancer Specialists South, Fort Myers

37203

Sarah Cannon Research Institute/Tennessee Oncology, Nashville

44106

University Hospitals Cleveland Medical Center, Cleveland

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02118

Boston Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Unknown

University College London, London

The Christie NHS Trust, Manchester

Southampton General Hospital, Southampton